Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration. In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC suffix |
|
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
DrugBank |
|
F |
|
H |
|
index2 label |
|
IUPAC name |
|
KEGG |
|
legal status |
|
legal UK |
|
legal US |
|
MedlinePlus |
|
n |
|
O |
|
PubChem |
|
routes of administration | |
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
tradename |
|
UNII |
|
width |
|
has abstract |
|
DailyMedID |
|
legal AU |
|
legal CA |
|
legal EU |
|
licence EU |
|
licence US |
|
pregnancy AU |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
CAS number |
|
ChEMBL |
|
DrugBank |
|
FDA UNII code |
|
KEGG |
|
MedlinePlus |
|
PubChem |
|